If biopharma had a Sputnik program, it would have to be stem cells. Research has been intensely competitive, and international. What has been missing, though, is clinical evidence of stem cell therapies’ efficacy and practicality. Last month, some of the world’s leading stem cell researchers, as well as interested pharma company experts, met at the ninth Annual World Stem Cells Regenerative Medicine Congress in London, to discuss the state of the science, and what they’re doing. Pluristem Theap...